D. E. Shaw & Co., Inc. Argenx Se Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Argenx Se stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 74,900 shares of ARGX stock, worth $68 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

74,900

Previous 61,800 21.2%

Holding current value

$68 Million

Previous $34.1 Million 62.17%

% of portfolio

0.04%

Previous 0.03%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$538.64 - $768.0 $16.7 Million - $23.9 Million	31,064 Added 22.52%	169,028 $125 Million
Q2 2025 Aug 14, 2025	SELL	$532.27 - $656.65 $65.1 Million - $80.3 Million	-122,361 Reduced 47.0%	137,964 $76 Million
Q1 2025 May 15, 2025	SELL	$571.0 - $671.75 $16 Million - $18.8 Million	-27,974 Reduced 9.7%	260,325 $154 Million
Q4 2024 Feb 14, 2025	BUY	$520.52 - $638.33 $97.2 Million - $119 Million	186,697 Added 183.75%	288,299 $177 Million
Q3 2024 Nov 14, 2024	BUY	$434.22 - $551.9 $25.1 Million - $31.9 Million	57,720 Added 131.53%	101,602 $55.1 Million

Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $21.1 Million - $26.8 Million	-59,249 Reduced 57.45%	43,882 $18.9 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $24.1 Million - $27.9 Million	-67,615 Reduced 39.6%	103,131 $40.6 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $13.7 Million - $20.5 Million	-40,540 Reduced 19.19%	170,746 $65 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $11.5 Million - $17 Million	31,033 Added 17.22%	211,286 $104 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $6.34 Million - $7.44 Million	-17,609 Reduced 8.9%	180,253 $70.3 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $19.8 Million - $23.9 Million	-59,165 Reduced 23.02%	197,862 $73.7 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $24.4 Million - $28.6 Million	-71,196 Reduced 21.69%	257,027 $97.4 Million
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $67.3 Million - $77.6 Million	196,089 Added 148.4%	328,223 $116 Million
Q2 2022 Aug 15, 2022	BUY	$269.58 - $378.88 $28.5 Million - $40.1 Million	105,869 Added 403.08%	132,134 $50.1 Million
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $6.33 Million - $8.73 Million	-24,870 Reduced 48.64%	26,265 $8.28 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $4.44 Million - $5.76 Million	16,311 Added 46.84%	51,135 $17.9 Million
Q3 2021 Nov 15, 2021	BUY	$295.0 - $350.58 $6.67 Million - $7.93 Million	22,626 Added 185.49%	34,824 $10.5 Million
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $241,940 - $301,044	941 Added 8.36%	12,198 $3.67 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $3.02 Million - $4.28 Million	11,257 New	11,257 $3.1 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $267,663 - $338,457	-1,242 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $158,280 - $289,038	1,242 New	1,242 $280,000
Q4 2018 Feb 14, 2019	SELL	$63.81 - $109.82 $7.2 Million - $12.4 Million	-112,906 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $5.73 Million - $7.33 Million	75,901 Added 205.11%	112,906 $8.56 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $2.77 Million - $3.71 Million	37,005 New	37,005 $3.07 Million

Others Institutions Holding ARGX

# of Institutions

525

Shares Held

26M

Call Options Held

589K

Put Options Held

320K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $50.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account